Two Cases of Chronic and Drug-Resistant Cutaneous Leishmaniasis as an Initial Presentation of the Underlying Lymphoproliferative Disorder

Document Type : Case Report

Authors

1 Resident, Department of Dermatology, Imam Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

2 Research Assistant, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

3 Associate Professor, Cutaneous Leishmaniasis Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Background: Cutaneous leishmaniasis is an infectious disease caused by the protozoa of Leishmania genus, which cause serious public health issues in endemic regions across 80 countries. The disease outcome is influenced by interaction between the parasite and immune system of its human host. Here, we report two cases of unusual and drug-resistant cutaneous leishmaniasis as an initial presentation of the underlying lymphoproliferative disorder.Case Report: Case 1 was a 43-year-old man with a history of cutaneous leishmaniasis presenting with an ulcerated and indurated plaque in proximity to the right eye along with ectropion, with multiple recurrences and resistance to multiple treatment plans. After multiple evaluations and hospitalizations, the patient was diagnosed with acute lymphoblastic leukemia (ALL). Case 2 was a 51-year-old man with a history of cutaneous leishmaniasis primarily presenting with an ulcerative papular lesion located on right forearm. The lesion was resistant to treatment, and two new ulcerated and indurated lesions appeared on the left ear and right zygoma with multiple recurrences and resistance to treatmen. During the course of treatment and further evaluations, chronic lymphocytic leukemia (CLL) was diagnosed.Conclusion: This case report presents ALL and CLL as possible underlying causes for resistance and recurrences in cutaneous leishmaniasis. Giving special attention to the patients’ signs and symptoms, as well as a thorough physical examination with proper paraclinical evaluations in patients with treatment failure, can be the key to identify underlying disorders.

Keywords


  1. Alvar J, Velez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012; 7(5): e35671.
  2. World Health Organization. Leishmaniasis [Online]. [cited 2019 Mar 14]; Available from: URL: https://www.who.int/en/news-room/fact-sheets/detail/leishmaniasis
  3. Amin M, Manisali M. Cutaneous leishmaniasis affecting the face: Report of a case. J Oral Maxillofac Surg 2000; 58(9): 1066-9.
  4. Rayatt SS, Moss AL. Cutaneous leishmaniasis. Br J Plast Surg 2000; 53(5): 443-5.
  5. Gonzalez C, Wang O, Strutz SE, Gonzalez-Salazar C, Sanchez-Cordero V, Sarkar S. Climate change and risk of Leishmaniasis in North America: predictions from ecological niche models of vector and reservoir species. PLoS Negl Trop Dis 2010; 4(1): e585.
  6. Alcover MM, Rocamora V, Guillen MC, Berenguer D, Cuadrado M, Riera C, et al. Case Report: Diffuse Cutaneous Leishmaniasis by Leishmania infantum in a Patient Undergoing Immunosuppressive Therapy: Risk Status in an Endemic Mediterranean Area. Am J Trop Med Hyg 2018; 98(5): 1313-6.
  7. van GJ, Carrillo E, Lopez-Velez R, Lynen L, Moreno J. Leishmaniasis in immunosuppressed individuals. Clin Microbiol Infect 2014; 20(4): 286-99.
  8. Al-Qattan MM. Extensive cutaneous leishmaniasis of the upper limb in a patient with leukemia. Ann Plast Surg 2002; 48(6): 670-1.
  9. Golino A, Duncan JM, Zeluff B, DePriest J, McAllister HA, Radovancevic B, et al. Leishmaniasis in a heart transplant patient. J Heart Lung Transplant 1992; 11(4 Pt 1): 820-3.
  10. Mirzabeigi M, Farooq U, Baraniak S, Dowdy L, Ciancio G, Vincek V. Reactivation of dormant cutaneous Leishmania infection in a kidney transplant patient. J Cutan Pathol 2006; 33(10): 701-4.
  11. Zandieh A, Zandieh B, Dastgheib L. Dissemination of localized cutaneous leishmaniasis in an organ transplant recipient: case report and literature review. Int J Dermatol 2013; 52(1): 59-62.